Kyprolis

Chemical Namecarfilzomib
Dosage FormInjection (intravenous; 10mg, 30mg, 60mg)
Drug ClassInhibitors
SystemBlood
CompanyAmgen
Approval Year2012

Indication

  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone.
  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with dexamethasone.
  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone.
  • Indicated for uses as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
Last updated on 12/16/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kyprolis (carfilzomib) Prescribing Information2021Onyx Pharmaceuticals, Inc., Thousand Oaks, CA
Document TitleYearSource
Multiple myeloma, version 3.2021.2020Journal of the National Comprehensive Cancer Network